| scholarly article | Q13442814 |
| P50 | author | Naveed Sattar | Q37378984 |
| Cem Gabay | Q66753936 | ||
| Arthur Kavanaugh | Q93106996 | ||
| P2093 | author name string | Iain B McInnes | |
| Micki Klearman | |||
| Katie Tuckwell | |||
| Jennifer Pulley | |||
| P2860 | cites work | Lipoprotein(a) as a cardiovascular risk factor: current status | Q24623225 |
| Acute-phase proteins and other systemic responses to inflammation | Q28296941 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease | Q33874567 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease | Q34684331 | ||
| High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a cohort study | Q34699546 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study | Q35352554 | ||
| IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans | Q35536380 | ||
| Patterns of cardiovascular risk in rheumatoid arthritis | Q35638493 | ||
| Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host | Q35753611 | ||
| High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease | Q35786190 | ||
| Integrated safety in tocilizumab clinical trials | Q35840716 | ||
| Thematic review series: The immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? | Q36049902 | ||
| Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis | Q37245188 | ||
| Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib | Q37257476 | ||
| Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions | Q37415092 | ||
| Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis | Q37801353 | ||
| Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review | Q37808889 | ||
| Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis | Q37977885 | ||
| Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm | Q38115132 | ||
| Update on lipoprotein(a) as a cardiovascular risk factor and mediator. | Q38132701 | ||
| An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 | ||
| Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis | Q42498499 | ||
| Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction | Q42540679 | ||
| HDL remodeling during the acute phase response | Q42580907 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study | Q43547020 | ||
| Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Q44165611 | ||
| Genetically elevated lipoprotein(a) and increased risk of myocardial infarction | Q44238417 | ||
| Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis | Q44360819 | ||
| Genetic variants associated with Lp(a) lipoprotein level and coronary disease. | Q50572117 | ||
| A rapid and simple quantification of human apolipoprotein E-rich high-density lipoproteins in serum. | Q52426365 | ||
| Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study | Q57232023 | ||
| Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis | Q74169414 | ||
| High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors | Q77406810 | ||
| Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis | Q83931811 | ||
| Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor | Q86290765 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adalimumab | Q348260 |
| tocilizumab | Q425154 | ||
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 1806-1812 | |
| P577 | publication date | 2015-11-27 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis | |
| P478 | volume | 75 |
| Q47108321 | Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. |
| Q64254840 | Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q97566245 | Biological therapy safety in chronic inflammatory arthropathy patients |
| Q63683454 | Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? |
| Q95277553 | Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q38937245 | Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study |
| Q92464675 | Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment |
| Q38813397 | Cardiovascular risk in patients with rheumatoid arthritis |
| Q92340149 | Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis |
| Q92628084 | Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis |
| Q90678059 | Cytokines and inflammation in adipogenesis: an updated review |
| Q40045794 | Efficiency of antibody therapy in demyelinating diseases. |
| Q39067604 | Immune resolution mechanisms in inflammatory arthritis |
| Q92122504 | Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q64885097 | Levels of Lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study. |
| Q58567872 | Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment |
| Q50284988 | Mechanisms of vascular comorbidity in autoimmune diseases |
| Q39371679 | Pathogenetic insights from the treatment of rheumatoid arthritis |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q91736923 | Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer |
| Q89748492 | Reflections on 'older' drugs: learning new lessons in rheumatology |
| Q91705028 | Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q38685086 | The role and therapeutic targeting of IL-6 in rheumatoid arthritis. |
| Q98615013 | Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19 |
| Q36234050 | Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. |
| Q48179396 | Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. |
| Q93196330 | Translating IL-6 biology into effective treatments |
Search more.